

Anti-Human/Mouse/Rat Phospho-AKT1 (Tyr326) Polyclonal Antibody

Polyclonal Antibody

Cat.NO.: PA01671

3th Edition

Description: The serine-threonine protein kinase AKT1 is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery.

Antigen: Synthesized peptide derived from human Akt around the phosphorylation site of Tyr326

Form:

How to use: 1.0 ml distilled water will be added to the product

Stability: Lyophilized product, 5 years at 2 – 8°C; Solution, 2 years at –20°C

Dilution: PBS (pH7.4) containing 1% BSA

Application: This antibody can be used for western blotting in concentration of 1?5?g/ml.

Specificity: Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.